ArticleThe Lancet regional health. Western Pacific2024

Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial.

Ming-Ci Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.